Find Clinical Trials

Inclusion Criteria: * Diagnosed with T2DM for at least 90 days prior to screening * Stable treatment with background insulin and other background glucose-lowering medication(s) * HbA1c value of ≥ 7% to ≤ 10.5% * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening Exclusion Criteria: * T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma * Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema * Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis. * Severe congestive heart failure (NYHA IV) * History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

Inclusion Criteria: For the screening cohort, the inclusion criteria are, women: * (1) who were 40 years of age or older (typical screening age range), and, * (2) who were asymptomatic, and, * (3) who underwent or scheduled to undergo a standard-of-care 2-view bilateral digital breast tomosynthesis screening exam. For the diagnostic cohort, the inclusion criteria are, women: * (1) who were 40 years of age or older, and, * (2) who underwent a standard-of-care 2-view bilateral digital breast tomosynthesis exam, and, * (3) who were assigned BI-RADS category 4 or 5 after diagnostic work-up and are scheduled for biopsy. Exclusion Criteria: * Males * Women less than 40 years old * pregnant or lactating women * women with physical limitations (e.g., kyphosis) that may prohibit UBCT exam * women who have received radiation treatments to the thorax * women who have participated in a prior breast clinical trial that gave additional radiation dose * women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as tuberculosis, and severe scoliosis.

Inclusion Criteria: * Aged 18 years or older * Literate * Diagnosed with breast cancer * Receiving taxane-based chemotherapy * Having a score of 1 or 2 for taste alteration according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) after the first cycle of chemotherapy * Willing to participate in the study and providing written informed consent Exclusion Criteria: * Having any communication barrier that prevents participation in the study * Having a diagnosed psychiatric disorder * Receiving radiotherapy * Having metastasis * Having a diagnosed physical disease that may affect food intake, such as ulcerative colitis or Crohn's disease * Receiving enteral or parenteral nutrition support

Inclusion Criteria: 1. asymptomatic clinically stable adults 2. aged 18-75 years 3. Both genders 4. Suboptimal BP (on stable medication) with SBP 135-160mmHG on ambulatory BP monitoring (AMBP) 5. Agreeable to no drug changes in coming 1 year 24 weeks 6. Agreeable to provide informed written consent form 7. Agreeable to have AMBP and ultrasonic (FMD \& IMT) scan third (baseline, 24 weeks and preferably 1 year) Exclusion Criteria: 1. relative contraindications to AMBP (e.g. atrial fibrillation) 2. severe osteoarthritis of knee 3. known secondary HT 4. pregnancy/breastfeeding 5. active malignancy 6. Serious coronary profiles, (unstable angina), renal or hepatic derangement 7. Need to change medications for control BP at 24 weeks ( SBP\>160 mmHg)

Inclusion Criteria: Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital. Exclusion Criteria: Severe pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \< 35 weeks of gestation, or with chronic medical conditions).

Key Inclusion criteria (Parts A, B, C, D and F): 1. Are males or females who can no longer have children, 2. Are 18 to 65 years old, 3. Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). For Part A (Optional group or cohort 3: Japanese participants only): 1. A total body weight of more than 45 kg (100 pounds). 2. Have 4 biological Japanese grandparents who were born in Japan. For Part E only: Adults with a documented doctor's-diagnosis history of asthma for at least 12 months before entering the study. 1\. Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). Key Exclusion criteria 1. Evidence or history of clinically significant medical conditions. 2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb). 3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. 4. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study. 5. Any history of parasitic infection requiring treatment within 28 days prior to screening. 6. Positive tuberculosis infection test result. 7. Part C only: Evidence or history of conditions interfering with the ability to taste. 8. Part D only: History of irregular bowel movements. 9. Part E only: Evidence of lung disease(s) other than asthma. 10. Part E only: Asthma exacerbation within 3 months prior to screening. 11. Part F only: History of acute narrow-angle glaucoma, untreated open-angle glaucoma, sleep apnea, respiratory insufficiency, myasthenia gravis or adverse reaction to midazolam or other benzodiazepines.

Inclusion Criteria: * Pregnant patient * Aged 18-50 years old * Planning to deliver in Mount Sinai Health System Exclusion Criteria: * Multiple gestation (i.e., twins) * Known fetal anomalies or genetic abnormalities

Inclusion Criteria: * All patients above 18 year diagnosed with schistozomiasis through history of exposure , serology , positive stool antigens ,Symmers' periportal fibrosis (the "clay pipe-stem" appearance) or Splenomegaly and suspected pulmonary hypertension through Probability Score" approach based on the 2022 ESC/ERS Exclusion Criteria: * All patients below 18 years old. * Left ventricular systolic or diastolic dysfunction. * Significant left-sided valvular heart disease. * severe chronic lung disease such as, Chronic obstructive pulmonary disease (COPD) ---- GOLD 4 and severe Interstitial lung disease (ILD). * Chronic Thromboembolic Pulmonary Hypertension. * Congenital heart diseases. * Severe hepatic or renal impairment unrelated to schistosomiasis. * Hemodynamically unstable patients. * Poor echocardiographic window preventing adequate RV assessment. * Active infection or acute systemic illness. * Refusal to participate in the study. * Significant arrhythmias affecting hemodynamic assessment (e.g., uncontrolled atrial fibrillation). * Previous heart or lung transplantation. * Pregnancy.

Inclusion Criteria: * Adults aged 18-50 years Kessler Psychological Distress Scale (K10) score \> 21 No systematic mindfulness or progressive muscle relaxation practice in the past 6 months (frequency \< 1 time per week) Normal or corrected-to-normal vision Voluntary participation with signed informed consent Exclusion Criteria: * Prior diagnosis of schizophrenia, bipolar disorder, or other severe mental disorders by a psychiatrist Suicidal plan, self-injury, or need for emergency psychological crisis intervention in the past month Currently receiving systematic psychotherapy or participating in other psychological intervention programs Started psychiatric medication within the past 3 months or on an unstable medication dosage History of epilepsy, severe brain injury, or other neurological disorders that may affect EEG measurement Severe vision or hearing impairment or other conditions preventing completion of study procedures

Inclusion Criteria: * Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening * T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s) * HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol) * Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening Exclusion Criteria: * Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma * Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema * Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis * Severe congestive heart failure (NYHA IV) * History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

Inclusion Criteria: 1. Aged between 11 to17 years; 2. With at least one mild mental health state as reported by Depression, Anxiety, and Stress Scale-21; 3. Able to read and understand Chinese; 4. Have access to a mobile phone and data plan. Exclusion Criteria: 1. With a diagnosis of hearing, visual, or physical impairments that may hinder study participation; 2. With a diagnosed history of major mental illnesses or other diagnosed medical conditions that may affect study participation.

Inclusion Criteria: 1. Patients who have fully understood the objectives, content, process of the study and possible adverse events, voluntarily serves as a subject and signs the informed consent form. 2. Subjects aged ≥18 and ≤75. 3. Male or female subjects with ECOG performance status scored 0-1. 4. Patients who were diagnosed with HER-2 negative advanced breast cancer by histopathology. 5. Patients with locally advanced,recurrent,or metastatic breast cancer. 6. Patients who had received chemotherapy regimens, including at least one taxanes or anthracyclines. 7. Patients with hormone receptor positive should have disease progression after endocrine therapy. 8. At least one measurable lesion present according to RECIST 1.1 criteria. 9. Expected survival time ≥ 12 weeks 10. Baseline routine blood tests is normal. 11. Liver and kidney function test results are normal. 12. Fertile males and females of childbearing potential must agree to use effective contraception (so do their partners, using hormonal or barrier contraception, or abstinence) during the study and within at least 6 months after the last dose. The blood or urine pregnancy test for female patients of childbearing potential prior to enrollment must be negative. Exclusion Criteria: 1. Patients who have received non-investigational anti-tumor therapies within 4 weeks prior to study drug administration. 2. Patients who have used Capecitabine or Utidelone within 6 months prior to randomization. 3. Patients with breast cancer with CNS metastases leptomeningeal metastases. 4. Patients with uncontrollable bone metastases,existing or recent risk of fracture, recent need for surgery or local radiotherapy, or other critical conditions. 5. Patients with uncontrollable pleural effusion,pericardial effusion or ascites requiring repeated drainage(once a month or more) 6. Patients with serious cardiovascular disease. 7. Patients with mental illnesses which are hard to control, patients who lack legal capacity or have limited legal capacity. 8. Patients with gastrointestinal disorders affecting oral administration. 9. Patients with active infections and need systemic therapy currently. 10. Patients with peripheral neuropathy grade≥2 during randomization. 11. Patients with toxicity grade ≥2 which caused by prior anti-tumor therapy.(NCI-CTCAE 5.0,except for what is considered no safety risk such as alopecia by investigator.） 12. Patients who have received any major surgery(except for diagnostic procedures such as biopsy）,or have sustained major trauma within 4 weeks to randomization;or is expected to undergo major surgery during the treatment. 13. Patients who have received radiotherapy within 2 weeks to randomization. 14. Patients who have received interventional therapy in another clinical trail or have received other investigational treatments. 15. Patients with other malignant tumor within 5 years to randomization excluding curatively treated cervical carcinoma in situ, cutaneous basal cell carcinoma or squamous cell carcinoma, and papillary thyroid carcinoma. 16. Patients with allergy of caster oil:patients with previous fluorouracil medication history with severe allergy or known dihydropyrimidine dehydrogenase (DPD) deficiency; 17. Pregnant or lactating patients. 18. Patients who, in the opinion of the investigator, are not suitable to participate in this study.

Inclusion Criteria: * Aged 18 to 65 years * Confirmed diagnosis of Type 2 Diabetes Mellitus * HbA1c between 6.5% and 13.0% * Not currently on insulin therapy * Has a primary care provider Exclusion Criteria: * Age below 18 or above 65 years * Blood pressure 160/100 mmHg or higher at screening * HbA1c below 6.5% or above 13.0% * Currently on insulin therapy * Pregnant or planning to become pregnant within the next 6 months * Serious medical conditions that would prevent safe participation in an exercise programme * Any physical or functional limitation that would prevent participation in resistance training * Underlying conditions that would not allow safe participation in the exercise intervention

Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated depression (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled MAO-A PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Inclusion Criteria: * Adults aged between 18 and 65 years. * Diagnosed with Rheumatoid Arthritis (RA) by a rheumatologist. * Disease in a stable phase (remission or low disease activity). * Access to a smartphone or tablet and sufficient proficiency in using mobile applications. * Cognitive sufficiency to provide written and verbal informed consent in Turkish. Exclusion Criteria: * Presence of acute RA flare-ups. * Severe psychiatric diagnoses (e.g., psychosis, bipolar disorder, or severe major depression). * Severe cognitive impairment or dementia. * Pregnancy. * Regular practice of meditation or mindfulness within the last 6 months. * Participation in any other stress management program within the last 3 months. * Receipt of mental health services within the last 6 months.

Inclusion/Exclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB. Inclusion Criteria: * Inclusions Criteria- Patients: 1. aged 18 years or older; 2. with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis; 3. intention to be treated at a participating institution; 4. with verbal fluency in English or Spanish; and 5. scheduled to be discussed at MDTB. * Inclusion criteria - Clinicians: All clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation. Exclusion Criteria: * Exclusion criteria - Patients: Individuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish. * Exclusion criteria - Clinician: Clinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.

Inclusion Criteria: 1-Age ≥ 18 years at time of enrolment. 2-Confirmed pre-capillary pulmonary hypertension on RHC performed at Assiut University Hospital: mPAP \> 20 mmHg AND PAWP ≤ 15 mmHg AND PVR ≥ 2 Wood Units. 3-WHO PH Clinical Group 1 (PAH), Group 3 (PH due to lung disease/hypoxia), or Group 4 (CTEPH / chronic thromboembolic PH) classification assigned by the PH-MDT. 4-Both CTPA and RHC performed within a maximum interval of 4 weeks. b. Exclusion criteria: 1. WHO PH Group 2 (PH due to left heart disease) or Group 5 (PH with unclear/multifactorial mechanisms) . 2. Active malignancy. 3. Pregnancy, confirmed or suspected. 4. Contraindication to iodinated contrast agent: eGFR \< 30 mL/min/1.73m² OR documented history of severe anaphylactic contrast reaction. 5. Inability to sustain breath-hold of ≥ 8 seconds (impairs CTPA quality). 6. Initiation or dose escalation of pulmonary vasodilator therapy (endothelin receptor antagonist, PDE5 inhibitor, soluble guanylate cyclase stimulator, or prostanoid) in the interval between CTPA and RHC, or within 4 weeks prior to CTPA. 7. Patient refusal to consent or inability to provide informed consent

Inclusion Criteria: * Age 50 to 70 years * Arterial hypertension * Coronary artery disease * Hospitalization for elective percutaneous coronary intervention * Coronary artery stenting during the current hospitalization * Requirement for dual antihypertensive therapy * Treatment with beta-blockers, lipid-lowering therapy, and antiplatelet therapy * Ability and willingness to provide written informed consent Exclusion Criteria: * Refusal or inability to provide informed consent * Acute coronary syndrome * Active malignancy * Pulmonary embolism * Chronic kidney disease stage 4-5 * Type 2 diabetes mellitus * Contraindications or intolerance to study medications, including bilateral renal artery stenosis, hyperkalemia, hyperuricemia, or gout * Women of reproductive age * Permanent or persistent atrial fibrillation * Planned staged coronary stenting * Heart failure with reduced ejection fraction * Any other condition that, in the investigator's opinion, may interfere with participation in the study or interpretation of study results

Inclusion Criteria: * Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter * At least once per year of follow-up data collection record Exclusion Criteria: * Patients with missing baseline or follow-up data * Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, malignancy, etc. * Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc. * Receiving medications with significant influence on hemodynamics

Inclusion Criteria: 1. Age 21 to 70 years. 2. Diagnosis of type 2 diabetes mellitus. 3. Agrees to consume durian for 2 weeks. 4. Body mass index 25 to 40 kg/m². Exclusion Criteria: 1. Known or suspected intolerance or allergy to durian. 2. Known skin reaction to adhesives used in a continuous glucose sensor. 3. Uncontrolled diabetes (HbA1c greater than 8.5%). 4. Severe hypertriglyceridemia (triglycerides greater than 4.5 mmol/L). 5. Smoking. 6. Previous gastrointestinal surgeries, including cholecystectomy, gastrectomy, bariatric surgery, or colectomy. 7. Inflammatory bowel disease. 8. Glomerular filtration rate less than 30 mL/min. 9. ALT greater than 3 times upper limit of normal. 10. AST greater than 3 times upper limit of normal. 11. Liver cirrhosis. 12. Significant alcohol consumption, defined as more than 20 g/day for women and more than 30 g/day for men. 13. Pregnant, breastfeeding, or intending to conceive during the study. 14. Current hemorrhoids or piles causing rectal bleeding during stool passage. 15. Systemic steroid use. 16. Insulin use. 17. Weight loss medications, including GLP-1 receptor agonists, orlistat, or phentermine. 18. Antibiotic, prebiotic, probiotic, vitamin C, or traditional Chinese medicine use in the last 1 month. 19. Uncontrolled thyroid disease. 20. Any factor likely to limit adherence to study protocol, including dementia, substance abuse, poor appointment adherence, or family concerns regarding participation